Trial Profile

A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of TAK-559 in the Treatment of Patients With Type 2 Diabetes Mellitus.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imiglitazar (Primary) ; Insulin
Indications Type 2 diabetes mellitus
Focus Adverse reactions; Pharmacodynamics; Registrational
Sponsors Takeda Global Research and Development Center

Most Recent Events

18 Dec 2008 Planned patient number added (348) as reported by ClinicalTrials.gov.
18 Dec 2008 Actual end date (Dec 2004) added as reported by ClinicalTrials.gov.
16 Oct 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com